Mark Goodwin, MD
Interventional Cardiology · Naperville, ILNPI 1639125867
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Edwards Lifesciences at 51.8% of the total. Reporting peaked in 2021 at $50,915 and has fallen 76.4% since, to $12,026 in 2025. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $286.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$63K
- Boston Scientific$19K
- Cordis US CORP.$16K
- Philips North America LLC$9K
- Asahi Intecc USA, Inc.$3K
- Medtronic$2K
- plus $9K from 35 others
Across 79 payments — averaging $2194.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$76K
- Edwards Lifesciences$20K
- Abbott$20K
- Medtronic$16K
- Surmodics, Inc.$15K
- Philips North America LLC$12K
- plus $15K from 3 others
What the payments were for
- Consulting fees$46,46038%
- Speaking & faculty fees$33,75028%
- Travel & lodging$20,12517%
- Food & beverage$20,09617%
- Education$20%
- Entertainment$6121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 110 | $62,704 |
| Boston Scientific | 55 | $19,235 |
| Cordis US CORP. | 17 | $15,886 |
| Philips North America LLC | 12 | $8,940 |
| Asahi Intecc USA, Inc. | 42 | $3,080 |
| Medtronic(2 entities) | 28 | $2,214 |
| Abbott | 33 | $2,147 |
| Siemens Medical Solutions USA, Inc. | 7 | $1,291 |
| Opsens Inc. | 17 | $907 |
| Shockwave Medical, Inc | 4 | $629 |
| Cardiva Medical, Inc. | 16 | $621 |
| Asahi Intecc CO., LTD. | 2 | $494 |
| Abiomed | 8 | $448 |
| Novartis | 16 | $323 |
| Corindus Inc. | 2 | $172 |
| Impulse Dynamics (USA) Inc. | 3 | $159 |
| W. L. Gore & Associates, Inc. | 3 | $154 |
| Shimadzu Precision Instruments, Inc. | 1 | $150 |
| Cardiac Dimensions, Inc. | 1 | $143 |
| Heartflow, Inc. | 1 | $131 |
| Cvrx, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Amgen | 5 | $88 |
| Penumbra, Inc. | 1 | $88 |
| Boehringer Ingelheim | 4 | $88 |
| Surmodics, Inc. | 3 | $84 |
| Teleflex LLC | 1 | $77 |
| Pfizer | 3 | $72 |
| Bard Peripheral Vascular, Inc. | 1 | $68 |
| Angiodynamics, Inc. | 1 | $64 |
| Johnson & Johnson | 3 | $55 |
| Merge Healthcare Incorporated | 1 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Lemaitre Vascular, Inc. | 3 | $45 |
| AstraZeneca | 2 | $44 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Cathworks, Inc. | 1 | $19 |
| Adagio Medical, Inc. | 1 | $18 |
| Venturemed Group, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$58,997
- SELUTION SLR PTA$9,036
- GENERAL VASCULAR ACCESS$9,000
- IGT Systems Und$7,815
- cardio$6,238
- Watchman$3,609
- STINGRAY$3,119
- ASAHI PTCA Guide Wire$1,469
- CorPath GRX$1,325
- GENERAL - THERAPIES$824
- SAPIEN 3 Ultra RESILIA$799
- EVOQUE$714
- (CN3) Zenition 90$618
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$565
- OptoWire$448
- MitraClip$421
- PERIPHERAL VASCULAR$374
- MitraClip System$334
- SYNERGY$291
- OPTIMIZER$284
How this compares
$121,045 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 174 | $209,584 |
| XareltoRivaroxaban | 153 | $169,592 |
| EntrestoSacubitril/Valsartan | 76 | $77,091 |
| Repatha SureclickEvolocumab | 40 | $46,823 |
| JardianceEmpagliflozin | 24 | $30,688 |
| BrilintaTicagrelor | 16 | $13,504 |
| VascepaIcosapent Ethyl | 12 | $12,830 |
| Metoprolol Succinate | 729 | $10,683 |
| ClopidogrelClopidogrel Bisulfate | 679 | $7,606 |
| Atorvastatin Calcium | 653 | $7,053 |
| Rosuvastatin Calcium | 445 | $5,206 |
| Dofetilide | 15 | $4,891 |
| Ranolazine ErRanolazine | 18 | $4,474 |
| Digoxin | 16 | $3,578 |
| Losartan Potassium | 345 | $3,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $209,584174 claims |
| Johnson & JohnsonXarelto | $55 | $169,592153 claims |
| NovartisEntresto | $323 | $77,09176 claims |
| Boehringer IngelheimJardiance | $88 | $30,68824 claims |
| AstraZenecaBrilinta | $44 | $13,50416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Naperville
- Krishna NagendranNaperville$39K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.